Quantification of intratumoral vascularization predicts metastasis in human invasive solid tumors (review).
Quantification of intratumoral vascularization predicts metastasis in human invasive solid tumors (review).
复制标题
肿瘤内血管化的量化可预测人类侵袭性实体瘤的转移（综述）。
DOI：
10.3892/or.1.1.7
复制
发表时间：
1994
期刊：
影响因子：
4.2
通讯作者：
G. Gasparini
中科院分区：
文献类型：
--
作者：
G. Gasparini
有实验证据表明，大多数实体瘤的肿瘤侵袭、进展和转移是血管生成依赖性的。血管生成肿瘤细胞表型的发生在恶性肿瘤期间表现为独立事件，并且从血管前阶段到血管阶段的转变可以通过多种机制实现。根据实验数据，可以合理地认为血管生成活性的测定是人类实体瘤中肿瘤侵袭性和转移性的标志。特别是，肿瘤血管生成的测定似乎是一种潜在的新预后标志物，可以识别低风险患者与高风险患者。在此基础上，最近进行了几项临床研究，将通过免疫细胞化学方法检测到的肿瘤内血管化程度与转移和/或预后相关联。总体而言，这些研究中的大多数发现，原发肿瘤的微血管密度与所测试的人类肿瘤（乳腺癌、非小细胞肺癌、前列腺癌、头颈癌和皮肤黑色素瘤）中转移的存在之间存在显着相关性。对于早期乳腺癌已经取得了很多经验。在这种肿瘤中，血管指数正在成为一种新型的重要预后工具，特别适用于识别适合全身辅助治疗的高风险淋巴结阴性患者。由于血管生成抑制剂药物已开始在临床试验中使用，因此对肿瘤个体血管生成活性的了解将来也可用作预测对这种新颖治疗方法的反应的标记。介绍并讨论了评估肿瘤血管形成的方法、临床结果、悬而未决的问题和未来的前景。
There is experimental evidence that tumour invasiveness, progression and metastasis of most solid tumours are angiogenesis-dependent. The onset of the angiogenic tumour cell phenotype behaves as an independent event during malignancy, and the switch from a prevascular to a vascular phase may be achieved by several mechanisms. From experimental data it is reasonable to think that determination of angiogenic activity is a marker of tumour aggressiveness and metastasis in human solid tumours. In particular, determination of tumour angiogenesis seems to be a potential new marker for prognosis, to recognize low versus high risk patients. On the above basis, recently, several clinical studies have been done to correlate the degree of intratumoral vascularisation, detected by immunocytochemical methods, with metastasis and/or prognosis. Overall, the majority of these studies found a significant correlation between microvessel density of the primary tumour and presence of metastasis in the human rumours tested (breast, non-small cell lung, prostatic and head and neck cancers and skin melanoma). Much experience has been obtained for early-stage breast carcinoma. In this tumour, vascular index is emerging as a novel important prognostic tool, particularly useful in identifying high risk node-negative patients eligible for systemic adjuvant therapy. Because angiogenesis-inhibitor drugs are beginning to be used in clinical trials, the knowledge of the individual angiogenic activity of the tumours may be used in the future also as a marker to predict response to such a novel therapeutic approach. The methods to assess tumour vascularisation, clinical results, open questions and future perspectives are presented and discussed.